Cupid Ltd

- There is no direct mention of any current or planned fundraising through equity in the transcript. - On debt, it is noted that Cupid Limited has short-term borrowings of around Rs. 8 crores, down from Rs. 11-12 crores previously, primarily for working capital. - There is no explicit discussion of new debt or equity fundraising plans in the call. - The management mentioned being open to exploring excellent opportunities, but no specific fundraising initiatives were indicated. - Overall, the transcript does not reveal any current or future fundraising through debt or equity being planned or underway.

- Cupid Limited has recently completed construction of a new diagnostics plant at Nasik. - Commercial production from the Nasik IVD (In Vitro Diagnostics) facility is expected to start from Q4 FY22. - The company is setting up instruments and starting experimental production in December 2021. - There have been delays in the commissioning of this plant due to supply chain and COVID-related labor/material shortages. - Cupid is exploring marketing plans and partnerships to boost the diagnostics vertical and considering use of tele-marketing for female condoms. - No explicit mention of other specific capex or strategic investments in the transcript, but emphasis is on production expansion, doubling revenue in next 2-3 years from existing and new product lines. - The company is increasing marketing budgets for female condoms, expected to be doubled depending on market response. In summary, the main current/future capital investment is in the diagnostics (IVD) plant at Nasik and related expansion activities.

- Cupid Limited aims to double its revenue in the next 2-3 years through development and expansion plans. - FY22 revenue target is approximately Rs.150 crores, with a PAT of at least Rs.20 crores. - FY23 revenue is expected to range between Rs.170-180 crores, driven partly by diagnostics sales, targeting a minimum 20% PAT margin. - Capacity utilization is strong, with 98% for male condoms and 97% for female condoms. - The company anticipates commercial production for IVD diagnostics starting Q4 FY22, expanding business verticals. - US market entry is expected to generate a minimum $5 million in the first year with 30-40% profit margins; Cupid will be the second player after Veru Pharma. - Marketing budget for female condoms in India may double, responding to slow domestic demand but significant growth potential. - Tender opportunities in Tanzania, South Africa, and India are expected to add substantial volume.

- Cupid Limited aims to double revenue in the next 2-3 years through expansion and a new CEO with international marketing, production, and financial expertise. - For FY22, expected revenue is around Rs.150 crores with a PAT minimum of Rs.20 crores. - For FY23, revenue is projected between Rs.170-180 crores with a net profit margin target of at least 20%. - US market entry expected to generate a minimum of $5 million in first-year revenue with 30-40% net profit margin. - Diagnostic (IVD) business commercial production to start Q4 FY22, expected to contribute to revenue growth. - Marketing budget likely to double in coming years to boost female condom sales, addressing low current domestic demand. - Expansion to government tenders and export markets (e.g., Tanzania, South Africa) expected to provide significant order inflows.

- Current order book is about Rs. 71 crores. - Expecting allocations from major tenders in Tanzania, South Africa, and Indian Government. - South Africa tender allocation expected in November 2021, involving 1 billion male condoms and 40 million female condoms per year for the next 3 years. - Awaiting new tender from Brazil expected early next year due to government budget cuts affecting current procurement. - Planning to participate in all tenders and explore export markets. - Established contacts with major buyers of IVD products, including potential outsourcing to major players like Mylan.